- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04953416
Fractional Non-ablative Laser for the Treatment of Hair Loss
Evaluation of Safety and Performance of Fractional Non-ablative Laser for the Treatment of Hair Loss - A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center, prospective, open label clinical trial with before-after study design. The study is designed to evaluate the feasibility of hair growth in female and male pattern hair loss (androgenic alopecia, alopecia areata) using a fractional non-ablative 1565nm ResurFX module.
This study will include up to 13 visits at the clinic: screening; at least 5 and up to 10 treatment (Tx) visits 14+/-3 days apart, and follow up (FU) visits at 1 and 3 months (each can be +/-7 days out of window) after the last treatment session. See Figure 3: Study Design for an illustration of the study design, for a summary of the study procedures and Table 1 for the schedule of times and events.
The study population will include up to 35 healthy subjects.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lviv, Ukraine, 79044
- AMG
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with noticeable alopecia of the following types: androgenic alopecia, telogen effluvium and alopecia areata
- Experiencing active hair loss within the last 1 months but no longer than 5 years
Male/Female hair pattern loss base on:
- Male presenting Norwood Hamilton Scale - Stage 1 and up to 4
- Female presenting Sinclair Grade I-IV
- Subjects in general good health
- Male and female, age 18-45 years old
- Women of child-bearing potential that agree to abstain from pregnancy or breastfeeding during the course of the study
- Women of child-bearing potential are required to use a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, NuvaRing, partner with vasectomy, Implanon or other approved devices, or abstinence) at least 3 months prior to enrollment and throughout the course of the study
- Willing to remain on the same diet/habits (per physician recommendation)
- Subject is willing and able to comply with protocol requirements and all study visits
- Subject is willing and able to provide a written informed consent
Exclusion Criteria:
Male/Female hair pattern loss base on:
- Male presenting Norwood Hamilton Scale - Stage 5 and up to 7
- Female presenting Sinclair Grade V
- Subjects who suffer from scarring alopecia or alopecia totalis
- Women who are pregnant, lactating, or less than 6 months post-lactation completion, possibly pregnant or planning a pregnancy during the study period
- Currently participating in or recently participated in another clinical trial (within the last 90 days)
- Has photosensitivity to laser treatment
Previous/Current Alopecia Treatment
- Has used during the six months prior to screening or is currently on any of the following medications: finasteride (or any other 5α-reductase inhibitor medications), medications with anti-androgenic properties, topical estrogen, progesterone, tamoxifen, anabolic steroids, medications which can potential cause hypertrichosis, oral glucocorticoids, lithium, phenothiazines, or other medication at the discretion of the investigator
- Has used during 6 months prior to screening or is currently on Minoxidil
- Has used oral phytotherapy within 2 months prior to study
Treatment area related
- Subject who color (any type of dye) their hair less than 2 weeks prior to treatment and can't withhold dying their hair during the course of the treatment period.
- Has any active skin infection in the scalp or scarring
- Has had hair transplants, scalp reduction, current hair weave or tattooing in the target area, which makes it difficult to perform treatment and assessments
- Has a chronic dermatological condition (eczema, psoriasis, infection, etc.) of the scalp
- Has ever received radiation therapy to the scalp
Medical Conditions
- History of cancer with the exception of (1) successfully treated basal cell or squamous cell carcinoma of the skin or (2) subjects with a history of successfully treated cancer that have been disease-free for five years (not in the treatment area)
- Any current cancer, or has had chemotherapy in the past year
- Bleeding disorders and/or using anti-platelet and anticoagulant medication
- Uncontrolled systemic disease (diabetes) or infection
- History of hypogonadism
- Has significant systemic illness
- Has a known underlying medical problem that could influence hair growth such as HIV infection, connective tissue disease, a thyroid condition, inflammatory bowel disease or other medical conditions, at the discretion of the investigator.
- Has used Accutane in the past 6 months
- Has a history of poor wound healing
- Has a history of keloid formation
- Has a history or evidence of heavy smoking (more than 1 package/20 cigarettes a day), any drug and/or alcohol abuse (over 500ml of 40% hard liquor a week) within the 12 months prior to study
- Significant concurrent illness that, in the investigator's opinion would interfere with the subject's participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Scalp treatment with ResurFX
|
The ResurFX module contains Erbium:Glass Fiber Laser Technology with wavelength of 1565 nm, which is transferred to the ResurFX handpiece via a fiber.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hair Density Improvement
Time Frame: week 0 and week 24 week follow up
|
evaluate the change in hair density in the target area hair count between baseline and follow up (at 1 month following last treatment), as assessed by scalp macro-imaging.
|
week 0 and week 24 week follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective Improvement
Time Frame: 24 week and 32 week follow up
|
Subjective global assessment of hair regrowth by subjects and the investigator at 1 and 3 months following last treatment using a 5-point improvement scale
|
24 week and 32 week follow up
|
Hair Density Improvement
Time Frame: week 0 and week 32 week follow up
|
Change in hair density in the target area between baseline and 3 month following last treatment, as assessed by scalp macro-imaging.
|
week 0 and week 32 week follow up
|
Adverse events
Time Frame: week: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 32
|
Skin safety throughout the study as determined by the investigator by examining the post-treatment occurrences of complications and adverse events
|
week: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 32
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Olga Yarish, MD, AMG clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LUM-ABU-M22-ResurFX-19-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alopecia
-
Siriraj HospitalCompletedRecalcitrant Alopecia Totalis | Recalcitrant Alopecia UniversalisThailand
-
Yale UniversityCompletedFibrosing Alopecia | Frontal Fibrosing Alopecia | Central Centrifugal Cicatricial AlopeciaUnited States
-
Aclaris Therapeutics, Inc.CompletedAlopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Yale UniversityCompletedAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Wake Forest University Health SciencesThe Skin of Color SocietyRecruitingCentral Centrifugal Cicatricial Alopecia (CCCA)United States
-
M.D. Anderson Cancer CenterNational Alopecia Areata FoundationActive, not recruitingAlopecia Areata | Alopecia Totalis | Alopecia Universalis | Autoimmune Hair Loss | Alopecia PartialisUnited States
-
King Saud UniversitySaudi Society of Dermatology and Dermatologic surgeryCompletedAlopecia Totalis | Alopecia Universalis | Ophiasic AlopeciaSaudi Arabia
-
Erasmus Medical CenterRecruitingAutoimmune Diseases | Alopecia | Alopecia Areata | Hair Diseases | Alopecia Totalis | Alopecia Universalis | Hair Loss | Alopecia DrugsNetherlands
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
EquilliumWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
Clinical Trials on 1565nm non ablative fractional laser
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Xijing HospitalRecruitingAndrogenic AlopeciaChina
-
Xijing HospitalRecruiting
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Bispebjerg HospitalCompleted
-
Massachusetts General HospitalUnknown
-
King's College Hospital NHS TrustAlexandra Hospital, Athens, GreeceCompleted
-
Bispebjerg HospitalLumenis Be Ltd.Completed
-
Cairo UniversityCompleted
-
Thaís Hofmann CachafeiroUnknown